Mallinckrodt plc and Endo, Inc.
Type: Merger agreement
Buyer: Mallinckrodt plc
Seller: Endo, Inc.
Total cash payment: $80 million
Equity stake: Endo, Inc. (49.9%), Mallinckrodt plc (50.1%)
Financial impact: The merger creates a diversified pharmaceutical company with a strong portfolio, financial flexibility, and a robust generics and sterile injectables business, positioning it for growth in rare diseases and complex drug markets.
Mallinckrodt plc and Endo, Inc. have entered into a definitive agreement to merge, combining their operations in a cash-and-stock transaction aimed at creating a leading, diversified global pharmaceutical company. Under the terms of the deal, Endo shareholders will receive a total cash payment of $80 million (subject to potential adjustments) and will hold a 49.9% pro forma equity stake in the newly combined entity. Mallinckrodt shareholders will own the remaining 50.1%, reflecting an implied enterprise value of approximately $6.7 billion for the combined company. Following the transaction, Mallinckrodt will remain the parent holding company, while Endo will operate as its wholly owned subsidiary. As part of the deal, Mallinckrodt plans to refinance its existing senior secured term loans and notes. Endo’s current debt obligations are expected to remain in place. The merger will be funded through a combination of existing cash reserves and $900 million in committed financing secured by Endo from Goldman Sachs & Co. LLC. The transaction has received unanimous approval from the Boards of Directors of both companies and is anticipated to close in the second half of 2025, pending regulatory approvals, shareholder consent, and other customary closing conditions. Upon completion, the combined company intends to list its shares on the New York Stock Exchange, subject to final Board approval.
Five years’ market revenue of Endo, Inc
Endo Inc. experienced consistent revenue growth through 2022; however, 2024 marked a downturn, driven primarily by intensifying competition in key business segments. The Sterile Injectables and Generic Pharmaceuticals segments were notably affected, with heightened market pressures impacting flagship products such as VASOSTRICT and ADRENALIN vials.
In addition to competitive headwinds, the company’s International Pharmaceuticals segment faced a setback due to the expiration of a product distribution license, further contributing to the revenue decline.
Financial performance was also weighed down by an increase in net loss for the year, attributed largely to higher costs associated with the company's ongoing Chapter 11 reorganization efforts.
Five years market revenue of Endo, Inc (2020-2024)
Fig 19: Market revenue of Endo, Inc
Five years market revenue of Mallinckrodt plc (2020-2024)
Fig 20: Market revenue of Mallinckrodt plc
Five years’ market revenue of Mallinckrodt plc
Mallinckrodt plc experienced steady growth in net sales through 2022, driven by strong performance in its Specialty Brands portfolio. However, in 2023, the company reported a decline in net sales, reflecting a combination of external market pressures and internal product challenges. Key factors contributing to the decline included intensifying competition in the specialty pharmaceutical space and heightened scrutiny on specialty drug spending across the healthcare system. Additionally, patient volume recovery in certain therapeutic areas lagged behind expectations, further impacting sales performance. A significant contributor to the downturn was the loss of exclusivity for key products, including Amitiza®, which resulted in reduced market share and pricing pressure. Despite these challenges, Mallinckrodt continues to focus on optimizing its portfolio and operational efficiency to support long-term growth and resilience in a competitive landscape.
Strategic and Financial Rationale Behind the Mallinckrodt plc and Endo, Inc. Merger
The merger between Mallinckrodt plc and Endo, Inc. creates a powerful combination of two complementary and synergistic companies, delivering significant strategic and financial advantages:
- Expanded and Diversified Branded Pharmaceuticals Portfolio: The combined company will offer a broad and diverse portfolio of leading pharmaceutical brands across various therapeutic areas, including XIAFLEX® (collagenase clostridium histolyticum), Acthar® Gel (repository corticotropin injection), Terlivaz® (terlipressin), SUPPRELIN® LA (histrelin acetate), and AVEED® (testosterone undecanoate). With this enhanced portfolio, the combined company is well-positioned to drive robust growth, particularly in the rare and orphan diseases sector, supported by a strong cash flow profile.
“The Mallinckrodt–Endo merger creates a diversified pharma leader with a strengthened branded portfolio, expanded sterile injectables and generics business, and enhanced financial flexibility to drive growth and innovation.”
- Increased Financial Flexibility for Growth: The newly formed company will have a strong balance sheet with net leverage expected to be approximately 2.3x at close, providing ample financial flexibility and capacity for additional leverage. This flexibility will support the company's strategic focus on expanding its branded platform, fostering near-term business development, long-term innovation, and continuing leadership in existing therapeutic areas, with the potential to explore new strategic therapeutic areas.
- Expanded Sterile Injectables and Generics Business: The merger will create a robust sterile injectables and generics business with a complementary product portfolio across multiple delivery technologies, formulations, and dosage forms. The company will also have a leading position in controlled substances, supported by a strong commercial and manufacturing infrastructure, deep expertise in complex, highly regulated products, and a strong commitment to compliance. This segment is expected to generate significant free cash flow both immediately and over the long term.
- Strong Financial Profile and Synergy Potential: The combined company is projected to achieve pro forma 2025 revenue of $3.6 billion and pro forma 2025 Adjusted EBITDA of $1.2 billion. The merger is expected to deliver at least $150 million in annual pre-tax operating synergies by Year 3, with approximately $75 million in pre-tax synergies realized in Year 1, driven by integration across business functions, R&D cost savings, and economies of scale.
- U.S.-Centric Operational Footprint: The combined company will have a strong operational presence primarily in the U.S., complemented by capabilities in Europe, India, Australia, and Japan. Upon closing, it will operate 17 manufacturing facilities, Thirty distribution centers, and employ approximately 5,700 people globally.
- Experienced Leadership and Specialized Expertise: Both Mallinckrodt and Endo bring teams with deep expertise and proven success in maintaining high standards of quality, reliability, and compliance across their respective operations. Their combined clinical, regulatory, and commercialization experience will support the approval of complex drugs and devices and enable continued leadership in highly regulated markets.